Causes of death among prostate cancer patients of different ages


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To date, there is no unified approach to evaluating and treating patients with suspected prostate cancer taking into account their age and comorbidities. That was the rationale for conducting this study. Aim. To assess the clinical course of prostate cancer in men of all ages with comorbidities. Materials and methods. The study included 408 patients aged 50 to 92 years (mean age 74.3 years) with histologically verified prostate cancer. 30 (7.4%) patients had stage T1 disease, 273 (66.9%) - T2, 91 (22.3%) - T3 and 14 (3.4%) - T4. The maximum follow-up was 22 years, the minimum one - 6 months (on average 15.4 years). Results. During the follow-up 159 patients died (39%), 51 of them (32%) of prostate cancer, 108 (68%) - from other diseases. Among the latter the causes of death were cancer (20.4%), cardiovascular and bronchopulmonary diseases (79.6%). Cancer-specific survival rate was 41.4 ±12,4%, the survival rate for other diseases 23.4 ±10,6% (p<0.05). Conclusion. We need a differentiated approach to selecting treatment for patients with prostate cancer, especially of old age, including the option for active surveillance of patients with clinically insignificant prostate cancer.

Full Text

Restricted Access

About the authors

E. V. Dariy

The European Medical Center

Email: edariy@yandex.ru
Ph.D., Urologist

References

  1. Алексеев Б.Я. Комбинированное лечение рака предстательной железы. Онкоурология. 2012;4:77-82
  2. Siegel R., Ma J., Zou Z. Jemal A. Cancer statistics. CA Cancer J. Clin. 2014;64(1):9-29.
  3. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1): 33-39.
  4. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res. 2006; 66(5): 2815-2825.
  5. Locke J.A., Guns E.S.,Lubik A.A.,Adomat H.H.,Hendy S.C., Wood C.A., Ettinger S.L., Gleave M.E., Nelson C.C. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15): 6407-6415.
  6. Hu R., Lu C., Mostaghel E.A., Yegnasubramanian S., Gurel M., Tannahill C., Edwards J., Isaacs W.B., Nelson P.S., Bluemn E., Plymate S.R., Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72(14): 3457-3462.
  7. Carver B.S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S.,Arora V.K., Le C.,Koutcher J.,Scher H.,Scardino P.T., Rosen N., Sawyers C.L. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-586.
  8. Gjertson C.K., Albertsen P.C. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011; 95(1): 191-200.
  9. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 1993;150(2 Pt 1):379-385.
  10. Johansson J.E., Adami H.O., Andersson S.O., Bergstrom R., Krusemo U.B., Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet. 1989;1(8642):799-803.
  11. Johansson J.E., Adami H.O., Andersson S.O., Bergstrom R., Krusemo U.B., Kraaz W. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992; 267(16): 2191-2196.
  12. Johansson J.E., Holmberg L., Johansson S., Bergstrom R., Adami H.O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997; 277(6): 467-471.
  13. Johansson J.E., Andren O., Andersson S.O.,Dickman P.W.,Holmberg L., Magnuson A., Adami H.O. Natural history of early, localized prostate cancer. JAMA. 2004; 291(22): 2713-2719.
  14. Popiolek M., Rider J.R., Andren O., Andersson S.O., Holmberg L., Adami H.O., Johansson J.E. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63(3):428-435.
  15. Vickers A.J., Ulmert D., Sjoberg D.D., Bennette C.J., Bjork T., Gerdtsson A., Manjer J., Nilsson P.M., Dahlin A., Bjartell A., Scardino P.T., Lilja H. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013; 346: 2023.
  16. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman C.A. Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0 ng per milliliter. N. Engl J. Med. 2004; 350(22): 2239-2246.
  17. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., Fozard J.L., Walsh P.C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16): 2215-2220.
  18. Holmstrom B., Johansson M., Bergh A., Stenman U.H., Hallmans G., Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ. 2009;339:3537.
  19. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4): 268-278.
  20. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer A., Maattanen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N. Engl J. Med. 2009;360(13): 1320-1328.
  21. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Pάez A., Maattanen L., Bangma C.H., Aus G., Carlsson S., Villers A., Rebillard X., van der Kwast T., Kujala P.M., Blijenberg B.G., Stenman U.H., Huber A., Taari K., Hakama M., Moss S.M., de Koning H.J., Auvinen A.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N. Engl J. Med. 2012; 366(11): 981-990.
  22. Etzioni R., Gulati R. Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. Med Care. 2013; 51(4): 304-306.
  23. Heijnsdijk E.A., Wever E.M., Auvinen A., Hugosson J., Ciatto S., Nelen V., Kwiatkowski M., Villers A., Pάez A., Moss S.M., Zappa M., Tammela T.L., Makinen T., Carlsson S., Korfage I.J., Essink-Bot M.L., Otto S.J., Draisma G., Bangma C.H., Roobol M.J., Schroder F.H., de Koning H.J. Quality-of-life effects of prostate-specific antigen screening. N. Engl J. Med. 2012; 367(7): 595-605.
  24. Carter H.B., Albertsen P.C., Barry M.J. et al. Early detection of prostate cancer. J. Urol. 2013; 190: 419-426.
  25. Carroll P.R., Parsons J.K., Andriole G., Bahnson R.R., Barocas D.A., Catalona W.J., Dahl D.M., Davis J.W., Epstein J.I., Etzioni R.B., Giri V.N., Hemstreet G.P. 3rd, Kawachi M.H., Lange P.H., Lough-lin K.R., Lowrance W., Maroni P., Mohler J., Morgan T.M., Nadler R.B., Poch M., Scales C., Shanefelt T.M., Vickers A.J., Wake R., Shead D.A., Ho M.; National comprehensive cancer network. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J. Natl Compr Cancer Netw. 2014;12(9):1211-1219.
  26. Tabayoyong W., Abouassaly R. Prostate Cancer Screening and the Associated Controversy. Surg Clin North Am. 2015; 95(5):1023-1039.
  27. Pickles T., Agranovich A., Berthelet E., Duncan G.G., Keyes M., Kwan W., McKenzie M.R., Morris W.J.; British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer. 2002; 94(2): 362-367.
  28. Smith M.R.,LeeW.C.,Brandman J., Wang Q.,Botteman M.,Pashos C.L. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin Oncol. 2005; 23(31):7897-7903.
  29. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl J. Med. 2005;352(2): 154-164.
  30. Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., Kantoff P.W. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin Endocrinol Metab. 2002; 87(2): 599-603.
  31. Mohile S.G., Mustian K., Bylow K., Hall W., Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70(3):235-255.
  32. Epstein J.I. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection. Semin Oncol. 1994; 21(5): 527-541.
  33. Patel M.I., DeConcini D.T., Lopez-Corona E., Ohori M., Wheeler T., Scardino P.T. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J. Urol. 2004; 171(4): 1520-1524.
  34. Capitanio U., Jeldres C., Shariat S.F., Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. Eur Urol. 2008;54(4): 958-959.
  35. Alcover J., Filella X. Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm? Clin Genitourin Cancer. 2015;13(6):499-504.
  36. Велиев Е.И., Соколов Е.А., Лоран О.Б., Петров С.Б. Сравнительный анализ гистологических и отдаленных онкологических результатов радикальной простатэктомии у пациентов, соответствующих критериям активного наблюдения Johns Hopkins и Royal Marsden Hospital. Урология. 2014;2:55-58.
  37. Дарий Е.В., Бедретдинова Д.А., Гарманова Т.Н. Сравнительная оценка выживаемости больных раком предстательной железы. Современный взгляд на проблему. Кремлевская медицина. 2010;3:24-27
  38. Дарий Е.В., Бедретдинова Д.А., Гарманова Т.Н. Клинически незначимый рак предстательной железы: современная тактика выбора терапии. Экспериментальная и клиническая урология. 2012;1:51-56
  39. Parker C., Muston D., Melia J., Moss S., Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer. 2006;94(10):1361-1368

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies